Semaglutide
STEP 2
Novo Nordisk · Phase 3 · Completed · Enrollment 1210
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Semaglutide 1.0 mg | 128 participants | 54 participants | 88 participants | n/r | 1 |
| Semaglutide 2.4 mg | 135 participants | 86 participants | 86 participants | n/r | 1 |
| Semaglutide placebo I/II | 37 participants | 11 participants | 48 participants | n/r | 1 |
A count stays a count. This page does not turn a count into a percent.